{"entity":{"id":"bp2301","kind":"drug","name":"BP2301","aka":[],"tldr":"BP2301 is an experimental autologous CAR-T cell therapy from BrightPath Biotherapeutics, in phase 1 trials for bone and soft tissue sarcoma and gynaecological cancers.","summary":"BP2301 is an autologous CAR-T cell therapy (non-viral gene transfer) from BrightPath Biotherapeutics. An autologous HER2-targeted CAR-T cell therapy made with non-viral gene transfer for HER2-expressing solid tumours. Its furthest stage is phase 1, for bone and soft tissue sarcoma and gynaecological cancers. No clinical trial naming it is registered on ClinicalTrials.gov. Company page says a phase 1 trial started in relapsed/advanced bone and soft tissue sarcoma and gynaecological cancers; no ClinicalTrials.gov entry found for BP2301 (likely a Japanese registry). It has not been shown to work in people.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"BrightPath Biotherapeutics: brightpathbio.com","url":"https://www.brightpathbio.com/pipeline/bp2301.html"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":["brightpath-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BP2301","modality":"Autologous CAR-T cell therapy (non-viral gene transfer)","mechanism":"An autologous HER2-targeted CAR-T cell therapy made with non-viral gene transfer for HER2-expressing solid tumours.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bp2301/","neighbours":{"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"brightpath-biotherapeutics","kind":"company","name":"BrightPath Biotherapeutics","route":"/companies/brightpath-biotherapeutics/"}]}}